The Abramson Cancer Center (ACC) has a long and successful track record of conducting innovative pilot and Phase I clinical trials, including studies targeting specific molecular pathways relevant to cancer, angiogenesis inhibition, cell-based therapy, and stem cell transplantation. Early Phase Clinical Research Support (EPCRS) has been particularly helpful in supporting the conduct of high priority, innovative, pilot and/or Phase I clinical trials. The pilot and Phase I trials that receive funding via this mechanism are of the highest priority for the ACC as they often lay the groundwork for future efficacy studies. Trials supported by EPCRS include both traditional ?investigator-initiated? studies of short duration (e.g., 1-2 years) and studies that result from collaborations with industry in which the ACC investigator is the primary contributor to the design and conduct of the trial and often has conducted the preclinical research that provided the rationale for the study. The primary focus of EPCRS during the project period has been to enable the conduct of innovative early phase trials. Funds have been used to support oncology research nurses and data managers for qualified, carefully selected trials. Studies supported by EPCRS, while highly meritorious, are often unfunded or under- funded, and thus unable to cover research nursing and/or data management costs adequately without such support. In addition, EPCRS funded studies are generally complex, and usually include novel biological correlative studies requiring expert study coordination. Consistent with this complexity, the EPCRS-supported research nurses and data managers are among our most highly trained staff. EPCRS enables this core group of experienced professionals to support ACC investigators in conducting ground-breaking translational research studies in a manner that responds to the needs of the investigators and matches the technical demands of the individual studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
United States
Zip Code
Chang, Changgee; Kundu, Suprateek; Long, Qi (2018) Scalable Bayesian variable selection for structured high-dimensional data. Biometrics :
Min, Eun Jeong; Safo, Sandra E; Long, Qi (2018) Penalized Co-Inertia Analysis with Applications to -Omics Data. Bioinformatics :
Singh, Rajnish Kumar; Lang, Fengchao; Pei, Yonggang et al. (2018) Metabolic reprogramming of Kaposi's sarcoma associated herpes virus infected B-cells in hypoxia. PLoS Pathog 14:e1007062
Pei, Yonggang; Singh, Rajnish Kumar; Shukla, Sanket Kumar et al. (2018) Epstein-Barr Virus Nuclear Antigen 3C Facilitates Cell Proliferation by Regulating Cyclin D2. J Virol 92:
Nicastri, Michael C; Rebecca, Vito W; Amaravadi, Ravi K et al. (2018) Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells. Mol Cell Oncol 5:e1395504
Micallef, Ivana N; Stiff, Patrick J; Nademanee, Auayporn P et al. (2018) Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report. Biol Blood Marrow Transplant 24:1187-1195
Medvec, Andrew R; Ecker, Christopher; Kong, Hong et al. (2018) Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium. Mol Ther Methods Clin Dev 8:65-74
Acosta, Jonuelle; Wang, Walter; Feldser, David M (2018) Off and back-on again: a tumor suppressor's tale. Oncogene 37:3058-3069
Crisalli, Lisa M; Hinkle, Joanne T; Walling, Christopher C et al. (2018) Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. Biol Blood Marrow Transplant 24:1203-1208
Mazaleuskaya, Liudmila L; Salamatipour, Ashkan; Sarantopoulou, Dimitra et al. (2018) Analysis of HETEs in human whole blood by chiral UHPLC-ECAPCI/HRMS. J Lipid Res 59:564-575

Showing the most recent 10 out of 1047 publications